Safety and Efficacy Study of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With Metastatic Pancreatic Cancer

NCT01303029 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Pancreatic Cancer

Interventions

DRUG: Gemcitabine+erlotinib
DRUG: Gemcitabine+erlotinib+capecitabine

Sponsor

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Collaborators

[object Object]